Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery

Medical Oncology

Volumn 31, Issue 2, 2014, Pages

  Tam, Moses ^a   Narayana, Ashwatha ^a   Raza, Shahzad ^a   Kunnakkat, Saroj ^a   Golfinos, John G ^a   Parker, Erik C ^a   Novik, Yelena ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Brain metastases; Breast cancer; HER2 positive; Stereotactic radiosurgery; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; FOLLOW UP; HUMAN; LOCAL THERAPY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIOTHERAPY; SALVAGE THERAPY; STEREOTACTIC RADIOSURGERY; WHOLE BRAIN RADIOTHERAPY; BRAIN TUMOR; BREAST TUMOR; CANCER STAGING; DISEASE COURSE; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDY; SURVIVAL RATE;

BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOSURGERY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84891411222     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0832-0     Document Type: Article

References (18)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41. doi:10.3322/caac.21149.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol. 2004;22(14):2865-72. doi:10.1200/JCO.2004.12.149.
3. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;101(4):810-6. doi:10.1002/cncr.20418.
4. Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004;15(11):1640-4. doi:10.1093/annonc/mdh432.
5. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107(4):696-704. doi:10.1002/cncr.22041.
6. Xue J, Peng G, Yang JS, Ding Q, Cheng J. Predictive factors of brain metastasis in patients with breast cancer. Med Oncol. 2013;30(1):337. doi:10.1007/s12032-012-0337-2.
7. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353 (16):1673-84. doi:10.1056/NEJMoa052122.
8. Bria E, Cuppone F, Fornier M, Nistico C, Carlini P, Milella M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109(2):231-9. doi:10.1007/s10549-007-9663-z.
9. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from regist HER. Clin Cancer Res. 2011;17(14):4834-43. doi:10.1158/1078-0432.CCR-10-2962.
10. Soffietti R, Ruda R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol. 2008;20(6): 676-84. doi:10.1097/CCO. 0b013e32831186fe.
11. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4): 745-51.
12. Horton JK, Halle J, Ferraro M, Carey L, Moore DT, Ollila D, et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys. 2010;76(4):998-1004. doi:10.1016/j.ijrobp.2009.03.027.
13. Sartor CI. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol. 2003;13(1):22-30. doi:10.1053/srao.2003.50003.
14. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-80.
15. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27(31):5278-86. doi:10.1200/JCO.2008.19. 8481.
16. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013. doi:10.1016/S1470- 2045(13) 70017-2.
17. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat. 2013;139(1):13-22. doi:10.1007/s10549-013-2525-y.
18. Lin NU. Brain metastases in HER2-positive breast cancer. Lancet Oncol. 2013. doi:10.1016/S1470-2045(13)70046-9.